State Street Corp Purchases 69,180 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS)

State Street Corp boosted its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 4.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,732,221 shares of the company’s stock after acquiring an additional 69,180 shares during the period. State Street Corp’s holdings in Atossa Therapeutics were worth $2,633,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ATOS. Bank of New York Mellon Corp lifted its position in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after purchasing an additional 399,041 shares during the period. Rhumbline Advisers bought a new stake in shares of Atossa Therapeutics during the second quarter worth approximately $161,000. Renaissance Technologies LLC raised its stake in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after buying an additional 164,540 shares during the last quarter. XTX Topco Ltd acquired a new position in Atossa Therapeutics in the second quarter valued at approximately $29,000. Finally, SG Americas Securities LLC boosted its stake in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after acquiring an additional 30,037 shares during the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Therapeutics Trading Down 3.1 %

ATOS stock opened at $0.94 on Wednesday. Atossa Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $2.31. The firm has a market cap of $118.77 million, a PE ratio of -4.29 and a beta of 1.21. The business’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.31.

Wall Street Analysts Forecast Growth

ATOS has been the topic of a number of analyst reports. StockNews.com downgraded Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Ascendiant Capital Markets upped their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, December 12th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.